ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.473,63
1,32%
S&P 500
5.744,21
-0,02%
Dow Jones
42.421,81
0,58%
Euro vs US Dollar
1,11506
-0,23%
Bitcoin
66.149,15
1,48%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. Can Fite BioPharma Ltd (CANF)

  7. Can Fite BioPharma Ltd (CANF) News

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:CANF
DatumZeitQuelleÜberschriftSymbolFirma
24/09/202413h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
24/09/202413h00GlobeNewswire Inc.Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary OsteoarthritisAMEX:CANFCan Fite BioPharma Ltd
16/09/202413h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
16/09/202413h00GlobeNewswire Inc.Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of HealthAMEX:CANFCan Fite BioPharma Ltd
09/09/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
06/09/202422h30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:CANFCan Fite BioPharma Ltd
06/09/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
30/08/202422h18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
30/08/202422h18Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersAMEX:CANFCan Fite BioPharma Ltd
30/08/202422h16Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementAMEX:CANFCan Fite BioPharma Ltd
30/08/202422h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CANFCan Fite BioPharma Ltd
29/08/202414h46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
29/08/202414h15GlobeNewswire Inc.Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAMEX:CANFCan Fite BioPharma Ltd
12/08/202412h45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
09/08/202412h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
09/08/202401h01GlobeNewswire Inc.Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross ProceedsAMEX:CANFCan Fite BioPharma Ltd
29/07/202413h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
29/07/202413h00GlobeNewswire Inc.Can-Fite Provides Namodenoson Patent UpdateAMEX:CANFCan Fite BioPharma Ltd
17/07/202413h00GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8AMEX:CANFCan Fite BioPharma Ltd
11/07/202413h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
11/07/202413h00GlobeNewswire Inc.Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
01/07/202413h00GlobeNewswire Inc.Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with NamodenosonAMEX:CANFCan Fite BioPharma Ltd
28/06/202413h00Business WirePositive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner VetbiolixAMEX:CANFCan Fite BioPharma Ltd
24/06/202413h00Business WireCan-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the LiverAMEX:CANFCan Fite BioPharma Ltd
10/06/202413h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
10/06/202413h00Business WireCan-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa StudyAMEX:CANFCan Fite BioPharma Ltd
07/06/202422h15Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]AMEX:CANFCan Fite BioPharma Ltd
05/06/202413h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
05/06/202413h00Business WireCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 StudyAMEX:CANFCan Fite BioPharma Ltd
29/05/202413h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
 Showing the most relevant articles for your search:AMEX:CANF

Kürzlich von Ihnen besucht

LSE
YK02
Citi Fun 24
TSXV
MRY.P
BIT
FFSQBE
Vontobel Financial Produ...
USOTC
ANGCF
Eon Lithium (PK)
BOV
R1HI34
Robert Half
BIT
UC5F5M
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten